Other languages BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
75.07 ^USD	+0.79%		-0.60%	-22.14%

May. 31	BioMarin Pharmaceutical Insider Sold Shares Worth $3,043,802, According to a Recent SEC Filing	MT
May. 17	Baird Downgrades BioMarin Pharmaceutical to Neutral From Outperform, Cuts Price Target to $72 From $104	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioMarin Pharmaceutical Insider Sold Shares Worth $3,043,802, According to a Recent SEC Filing	May. 31
Baird Downgrades BioMarin Pharmaceutical to Neutral From Outperform, Cuts Price Target to $72 From $104	May. 17
Transcript : BioMarin Pharmaceutical Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM	May. 15
Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing	May. 13
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT 1:00pm ET, in Las Vegas, NV	May. 09
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV	May. 08
Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing	May. 06
New Data for BioMarin's VOXZOGO for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society Annual Meeting	May. 06
Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	May. 04
BioMarin Pharmaceutical Inc. Announces That Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	May. 04
ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna...	May. 03
BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says	Apr. 29
Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $85 From $83, Maintains Sector Perform Rating	Apr. 25
Wells Fargo Adjusts Price Target on BioMarin Pharmaceutical to $110 From $100, Maintains Overweight Rating	Apr. 25
Transcript : BioMarin Pharmaceutical Inc., Q1 2024 Earnings Call, Apr 24, 2024	Apr. 24
BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours	Apr. 24
BioMarin: Q1 Earnings Snapshot	Apr. 24
(BMRN) BIOMARIN PHARMACEUTICAL Forecasts Fiscal Year 2024 EPS Range $2.75 - $2.95	Apr. 24
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 Revenue $648.8M	Apr. 24
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 EPS $0.71	Apr. 24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Other languages

Filters